Rather than just establishing a superiority in controlling symptoms and gradients, great expectations lie in the demonstration that myosin inhibitors may be true modifiers of the long-term trajectory of disease.
Aficamten vs Metoprolol: A Turning Point in Obstructive Hypertrophic Cardiomyopathy Care?: The MAPLE-HCM Results / Heidecker, Bettina; Olivotto, Iacopo. - In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. - ISSN 1558-3597. - STAMPA. - (2026), pp. 1-4. [10.1016/j.jacc.2025.11.051]
Aficamten vs Metoprolol: A Turning Point in Obstructive Hypertrophic Cardiomyopathy Care?: The MAPLE-HCM Results
Olivotto, Iacopo
2026
Abstract
Rather than just establishing a superiority in controlling symptoms and gradients, great expectations lie in the demonstration that myosin inhibitors may be true modifiers of the long-term trajectory of disease.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0735109725103598-main.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
285.25 kB
Formato
Adobe PDF
|
285.25 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
